DOI: 10.1007/s13311-016-0510-y Pages: 321-332
Article Type: Review

New Directions in Anti-Angiogenic Therapy for Glioblastoma

1. Massachusetts General Hospital, Stephen E. and Catherine Pappas Center for Neuro-Oncology

2. Massachusetts General Hospital, Department of Radiation Oncology

3. Massachusetts General Hospital, Department of Hematology/Oncology

Correspondence to:
Tracy T. Batchelor
Tel: +1-617-6431938
Email: tbatchelor@mgh.harvard.edu

Close

Abstract

Anti-angiogenic therapy has become an important component in the treatment of many solid tumors given the importance of adequate blood supply for tumor growth and metastasis. Despite promising preclinical data and early clinical trials, anti-angiogenic agents have failed to show a survival benefit in randomized controlled trials of patients with glioblastoma. In particular, agents targeting vascular endothelial growth factor (VEGF) appear to prolong progression free survival, possibly improve quality of life, and decrease steroid usage, yet the trials to date have demonstrated no extension of overall survival. In order to improve duration of response and convey a survival benefit, additional research is still needed to explore alternative pro-angiogenic pathways, mechanisms of resistance, combination strategies, and biomarkers to predict therapeutic response.

To access the full text, please Sign in

If you have institutional access, please click here

  • Online: Jan 12, 2017

Article Tools